Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial

Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial

Abstract Background Psoriasis, a chronic, immune-mediated, inflammatory disease, affects 2‒3% of the population. Tyrosine kinase 2 (TYK2) mediates cytokine signaling involved in adaptive [interleukin (IL)-12, IL-23] and innate (type-I interferons) immune responses; IL-23–driven T-helper (Th)17 pathw...

Olles dieđut

Bibliográfalaš dieđut
Váldodahkkit: Ian M. Catlett, Lu Gao, Yanhua Hu, Subhashis Banerjee, James G. Krueger
Materiálatiipa: Artihkal
Giella:English
Almmustuhtton: Adis, Springer Healthcare 2024-09-01
Ráidu:Dermatology and Therapy
Fáttát:
Cytokine
Deucravacitinib
Pharmacodynamics
Psoriasis
Tyrosine kinase 2
Liŋkkat:https://doi.org/10.1007/s13555-024-01262-5

Interneahtta

https://doi.org/10.1007/s13555-024-01262-5

Geahča maid